Radioimmunoscintigraphy of ovarian cancer with 131-iodine labeled OC-125 antibody fragments

Abstract

Radioimmunoscintigraphy (RIS) with 131I labeled OC-125 F(ab')2 monoclonal antibody fragments was prospectively studied in 43 women for primary diagnosis and follow up of ovarian cancer. Total body planar photoscans with a scintillation camera were performed one to seven days after antibody application and results were compared with operation and or CT examination. By the region of interest technique the tumor to non tumor tissue ratio (T/N) was calculated in vivo. Sensitivity in primary diagnosis was 100% (10/10), specificity 33% (1/3). For local recurrency, sensitivity was 86% (19/22), for metastatic loci 80% (17/21). Specificity was 75% and 50%. T/N ratio was in the rage from 1.3 to 2.8. Sensitivity for ovarian cancer is high in primary diagnosis and follow up. By the region of interest technique it is possible to detect small recurrencies and to presume peritoneal carcinosis. Antibody accumulations in diseases different from ovarian cancer however diminish specificity.

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences

“…of patients 13-45) for different kinds of adenocarcinomatous lesions [4,9,16,20,24,25]. The high value of 96.6% for locoregional specificity confirms the results of a pilot clinical trial using 99mTc-MAb-170 that showed no false-positive result in six patients with cancer of the ovary or the fallopian tube [15].…”

“…of patients: 10-45). These findings appear to indicate that radioimmunoscintigraphy with 99mTc-MAb-170 represents a reliable diagnostic tool in cases of ovarian carcinoma [2,6,7,13,[15][16][17][18][19][20][21][22][23].…”

Tumor Markers in Gynecologic Cancer

“…Barzen et al [37] (in a study utilizing 1311-labelled OC 125), reported a sensitivity of 100% and a specificity of 33% in the primary detection of ovarian cancer. In detect ing a recurrent ovarian cancer, the specificity of radionu clide imaging increases.…”

Radioimmunotherapy with90Y-Labeled Monoclonal Antibodies in a Nude Mouse Ovarian Cancer Model

“…The aim of the present study was to test intratumoral injection of a 9oY-labeled tumor-nonspecific antibody in a nude mouse model. We selected OC 125 (8) as antibody for this model, since it has been clinically used under various auspices (9)(10)(11)(12)(13) and also carefully studied in mouse K . KAIREMO ET AL.…”